Cargando…

Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer

PURPOSE: To determine the most powerful cancer antigen 125 (CA125)-related prognostic factor for advanced epithelial ovarian cancer (EOC) and to identify cut-off values that distinguish patients with a poor prognosis from those with a good prognosis. MATERIALS AND METHODS: We included 223 patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Maria, Chang, Min Young, Yoo, Hanna, Lee, Kyung Eun, Chay, Doo Byung, Cho, Hanbyoul, Kim, Sunghoon, Kim, Young Tae, Kim, Jae-Hoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800345/ https://www.ncbi.nlm.nih.gov/pubmed/26996555 http://dx.doi.org/10.3349/ymj.2016.57.3.580

Ejemplares similares

Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy
por: Lee, Yong Jae, et al.
Publicado: (2018)

ATP-Based Chemotherapy Response Assay in Primary or Recurrent Ovarian and Peritoneal Cancer
por: Lee, Maria, et al.
Publicado: (2014)

Significance of the serum CA-125 level in intrauterine insemination cycles
por: Choe, Seung Ah, et al.
Publicado: (2011)

Clinical Significance of Serum CA-125 in Korean Females with Ascites
por: Bae, So Young, et al.
Publicado: (2013)

Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models
por: Eoh, Kyung Jin, et al.
Publicado: (2018)

Significance of serum CA125 level in surgically resected cervical adenocarcinoma with adverse features
por: Kim, Nalee, et al.
Publicado: (2021)

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2017)

Prognostic implications of forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in epithelial ovarian cancer
por: Han, Gwan Hee, et al.
Publicado: (2019)

Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas
por: Choi, Ji Hui, et al.
Publicado: (2018)

Establishment of five immortalized human ovarian surface epithelial cell lines via SV40 T antigen or HPV E6/E7 expression
por: Shin, Ha-Yeon, et al.
Publicado: (2018)

Makorin Ring Finger Protein 1 as Adjunctive Marker in Liquid-based Cervical Cytology
por: Lee, Maria, et al.
Publicado: (2016)

Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy
por: Eoh, Kyung Jin, et al.
Publicado: (2017)

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
por: Lee, Yong Jae, et al.
Publicado: (2020)

Clinical Significance of Microsatellite Instability in Sporadic Epithelial Ovarian Tumors
por: Yoon, Bo-Sung, et al.
Publicado: (2008)

Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer
por: Kim, Yoo-Na, et al.
Publicado: (2019)

Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study
por: Kim, Hee Seung, et al.
Publicado: (2016)

The role of S100A14 in epithelial ovarian tumors
por: Cho, Hanbyoul, et al.
Publicado: (2014)

Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women
por: Cho, Hye Yon, et al.
Publicado: (2015)

Prognostic value of serum CA-125 in patients with advanced epithelial ovarian cancer followed by complete remission after adjuvant chemotherapy
por: Moon, Jong Ho, et al.
Publicado: (2013)

Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer
por: Lee, Yong Jae, et al.
Publicado: (2022)

A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer
por: Park, Junsik, et al.
Publicado: (2020)

DNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis in Endometrial Cancer
por: Kim, Jisup, et al.
Publicado: (2018)

Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Lee, Yong Jae, et al.
Publicado: (2020)

The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4
por: Han, Kyung Hee, et al.
Publicado: (2019)

Significant simultaneous changes in serum CA19-9 and CA125 due to prolonged torsion of mature cystic teratoma of the ovary
por: Suh, Dong Soo, et al.
Publicado: (2014)

Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center
por: Lee, Yong Jae, et al.
Publicado: (2018)

Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis
por: Shin, Kyung-Hwa, et al.
Publicado: (2020)

Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer
por: Kim, Yun-Ji, et al.
Publicado: (2018)

Prognostic value of complete metabolic response on (18)F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2022)

CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer
por: Peters-Engl, C, et al.
Publicado: (1999)

Tetraspanin 1 promotes endometriosis leading to ovarian clear cell carcinoma
por: Shin, Ha‐Yeon, et al.
Publicado: (2021)

Prognostic significance of supradiaphragmatic lymph node metastasis detected by (18)F-FDG PET/CT in advanced epithelial ovarian cancer
por: Lee, In Ok, et al.
Publicado: (2018)

Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study
por: Lee, Yong Jae, et al.
Publicado: (2018)

Early Assessment of Response to Neoadjuvant Chemotherapy with (18)F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer
por: Chung, Young Shin, et al.
Publicado: (2020)

External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma
por: Lee, Jung-Yun, et al.
Publicado: (2017)

Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients
por: Eoh, Kyung Jin, et al.
Publicado: (2017)

Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy
por: Tuxen, M K, et al.
Publicado: (2001)

Genetic analysis of ovarian microcystic stromal tumor
por: Lee, Jae Hoon, et al.
Publicado: (2016)

Prognostic Significance of CD109 Expression in Patients with Ovarian Epithelial Cancer
por: Kim, So Young, et al.
Publicado: (2019)

Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jnuets4mmj36mchoua6a0dmeq4